Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences.
about
Human gene therapy and imaging in neurological diseases.Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Feline immunodeficiency virus as a gene transfer vector in the rat nucleus tractus solitariiCalcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's modelsGene therapy in epilepsy.Recent advances in the pharmacology of neurological gene therapy.Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.Transcriptional Response of Human Neurospheres to Helper-Dependent CAV-2 Vectors Involves the Modulation of DNA Damage Response, Microtubule and Centromere Gene Groups.Regulatable gene expression systems for gene therapy applications: progress and future challenges.Non structural protein of avian influenza A (H11N1) virus is a weaker suppressor of immune responses but capable of inducing apoptosis in host cellsGene therapeutics: the future of brain tumor therapy?Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialEfficacy of nonviral gene transfer in the canine brain.Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.Mechanisms and implications of adaptive immune responses after traumatic spinal cord injuryImmunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?pUNISHER: a high-level expression cassette for use with recombinant viral vectors for rapid and long term in vivo neuronal expression in the CNS.Chitosan nanoparticles in drug therapy of infectious and inflammatory diseases.The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation.Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses.Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression.Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses.Absence of an intrathecal immune reaction to a helper-dependent adenoviral vector delivered into the cerebrospinal fluid of non-human primates.Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice.Diffuse encephaloventriculitis and substantial leukoencephalopathy after intraventricular administration of recombinant adenovirus.Gene therapy for Parkinson's disease
P2860
Q31023442-EC1B3FC8-140C-4D4C-A2B8-9A6408121B37Q33641230-893DCCBF-3B1A-4F3D-AC92-1C0C8D1790F0Q33778126-94683DD3-45F0-4EB5-B2D6-8DD01D833327Q33947378-B505E3C9-8A0F-41C5-8D1C-F632A467CD00Q33960096-EBE7802D-C777-4FD6-8A55-F7009A57D93AQ33985688-8A84630A-7E7C-4617-BDA2-80FC1BCDF52EQ34102305-8D97C1E5-173E-4A17-900B-CA7EA8120F19Q35710695-0DA0D542-8747-4037-BA57-D0AE85CF1061Q36157542-5E64509C-1A96-43E8-BFF3-754E335CA61FQ36376390-20D3056C-B406-41B9-8952-D31B9D155F6DQ36532106-6B0BB138-0105-4741-94A7-39ED2161FB93Q36534329-75036BEE-241D-4765-BD61-2BF01CE17CC6Q36658314-9EC00330-D391-40FA-A26C-A77C85E6F61EQ36960666-F96BB307-04DE-4500-841A-111003E3671DQ37233232-16283EBC-5EEC-4DAA-9DAE-7C1B52AA557CQ37245006-E3C24029-FA46-45AC-880D-F8690AF6702FQ37399627-0CF18F07-0236-4157-82DE-382B8ACE6544Q38103856-7E33AF3B-7133-40C9-B0F2-9EB276CD34FCQ38461882-96DEB349-77DC-4B89-9F44-57971633082BQ38810516-84DCFDC0-91CB-4E25-B05C-B330BFC89286Q39737653-3A524407-CD12-4EBE-BC2E-CBE0D546D93AQ40258000-C65CF899-5C3F-41B3-B5AB-860536E01BEDQ40413612-C3489DF7-ABDE-45CA-B748-4B1963453071Q42613158-D9A7E021-2AB7-41A7-875D-09C7D5138B9FQ45862358-18BB3AE3-5538-4E10-B976-15B0ADC7A2AFQ45872162-93A06179-4BF6-4EAE-AC11-E838271AC2B4Q48706428-4E01AC8C-74E8-4731-86D6-D76AEE750838Q48859616-4C8AE8B0-780D-461E-BA9E-0E075CCEF074Q58913419-BE277618-7C70-4F34-90B1-BA94B2546B69
P2860
Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Inflammation and adaptive immu ...... mechanisms, and consequences.
@ast
Inflammation and adaptive immu ...... mechanisms, and consequences.
@en
type
label
Inflammation and adaptive immu ...... mechanisms, and consequences.
@ast
Inflammation and adaptive immu ...... mechanisms, and consequences.
@en
prefLabel
Inflammation and adaptive immu ...... mechanisms, and consequences.
@ast
Inflammation and adaptive immu ...... mechanisms, and consequences.
@en
P356
P1433
P1476
Inflammation and adaptive immu ...... mechanisms, and consequences.
@en
P2093
Lowenstein PR
P2888
P304
P356
10.1038/SJ.GT.3302048
P577
2003-06-01T00:00:00Z
P5875
P6179
1013463770